Applied Research for Populations Around Hazardous Waste Sites, 44925-44929 [05-15412]
Download as PDF
Federal Register / Vol. 70, No. 149 / Thursday, August 4, 2005 / Notices
Peoples State Bank of Comfrey,
Comfrey, Minnesota, to a federal savings
bank, to be known as Choice Financial
Savings Bank, Comfrey, Minnesota,
pursuant to section 225.28(b)(4)(ii) of
Regulation Y.
2. Choice Financial Holdings, Inc.,
Grafton, North Dakota to operate a
savings association through the
conversion of Peoples State Bank of
Comfrey, Comfrey, Minnesota, to a
federal savings bank, to be known as
Choice Financial Savings Bank,
Comfrey, Minnesota, pursuant to section
225.28(b)(4)(ii) of Regulation Y.
Board of Governors of the Federal Reserve
System, July 29, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–15381 Filed 8–3–05; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Committee on Vital and Health
Statistics; Meeting
Pursuant to the Federal Advisory
Committee Act, the Department of
Health and Human Services (HHS)
announces the following advisory
committee meeting.
Name: National Committee on Vital
and Health Statistics (NCVHS),
Subcommittee on Privacy and
Confidentiality.
Time and Date: August 16, 2005, 1:30
p.m.–5 p.m. August 17, 2005, 9 a.m.–5
p.m.
Place: Hotel Monaco, 501 Geary
Street, San Francisco, CA 94102, (415)
292–0100.
Status: Open.
Purpose: The meeting will focus on
privacy and confidentiality issues
related to electronic health records and
the development of a National Health
Information Network (NHIN). The
Subcommittee will hear from witnesses
who have been asked to respond to
questions posted on the Subcommittee’s
Web site https://www.ncvhs.hhs.gov/.
The questions focus on design options
for a NHIN, related privacy and
confidentiality concerns, issues around
patient control of content and access to
NHIN records, and broader issues
around privacy and confidentiality of
personal health information and
building the public trust in the NHIN.
Contact Person for More Information:
Substantive program information as
well as summaries of meetings and a
roster of committee members may be
obtained from Maya A. Bernstein, Lead
Staff for Subcommittee on Privacy and
VerDate jul<14>2003
16:23 Aug 03, 2005
Jkt 205001
44925
Confidentiality, Office of the Assistant
Secretary for Planning and Evaluation,
434E Hubert H. Humphrey Building,
200 Independence Avenue, SW., 20201;
telephone (202) 690–7100; or Marjorie
S. Greenberg, Executive Secretary,
NCVHS, National Center for Health
Statistics, Centers for Disease Control
and Prevention, 3311 Toledo Road,
Room 2402, Hyattsville, Maryland
20782, telephone (301) 458–4245.
Information also is available on the
NCVHS home page of the HHS Web site:
https://www.ncvhs.hhs.gov/, where
further information including an agenda
will be posted when available.
Should you require reasonable
accommodation, please contact the CDC
Office of Equal Employment
Opportunity on (301) 458–4EEO (4336)
as soon as possible.
generate the appearance or hide the
presence of a relationship between
exposure to hazardous substances and
adverse health effects. The presence of
environmental contamination and an
adverse health effect does not
automatically demonstrate evidence of a
causal relationship. Beginning in 1992,
ATSDR developed a research agenda to
address some of these questions.
Research under this agenda continues to
be conducted, but additional research is
needed. Therefore, projects conducted
under this program announcement will
focus on those questions that have the
greatest relevance toward determining
the relationship of adverse health effects
among persons exposed to hazardous
substances.
Examples of relevant ATSDR
activities are presented below:
Dated: July 29, 2005.
James Scanlon,
Acting Deputy Assistant Secretary for Science
and Data Policy, Office of the Assistant
Secretary for Planning and Evaluation.
[FR Doc. 05–15454 Filed 8–3–05; 8:45 am]
Evaluation of Persons Exposed to
Tremolite Asbestos Contaminated
Vermiculite
Asbestos contaminated vermiculite
ore was mined and processed in Libby,
Montana, from the early 1920s until
1990. ATSDR has completed a medical
screening program, a mortality review
and a Public Health assessment in
Libby. Based on these studies and
additional evaluation conducted by
ATSDR, EPA and the State of Montana,
people who worked in the Libby mine
or processing facilities and people who
lived in the Libby community were
exposed to asbestos-contaminated
vermiculite. Nearly eighteen percent of
medical screening participants had
radiographic pleural abnormalities
consistent with asbestos exposure.
Mortality due to lung cancer and
asbestosis was also found to be elevated
in Libby. ATSDR has also implemented
a Tremolite Asbestos Registry (TAR) of
exposed persons and has funded the
State of Montana to conduct additional
periodic medical surveillance for
eligible persons.
Additionally, records indicate that the
vermiculite ore from Libby was shipped
to over 200 locations around the U.S. for
handling and/or processing into various
commercial and consumer products.
Twenty-eight ‘‘Phase 1 Sites’’ have been
identified based on a variety of factors
such as tonnage of ore received,
population density, numbers of workers,
etc. Health statistics reviews (to evaluate
mortality and cancer registry data) are
currently being completed in sixteen
states and mesothelioma surveillance
has been initiated in three states (New
York, Wisconsin and New Jersey). In
addition, ATSDR has funded a
comprehensive community exposure
assessment project in a community
receiving the ore. This work addresses
BILLING CODE 4151–05–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
Applied Research for Populations
Around Hazardous Waste Sites
Announcement Type: New.
Funding Opportunity Number: CDC–
RFA–TS05–110.
Catalog of Federal Domestic
Assistance Number: 93.161.
DATES: Application Deadline: August
29, 2005.
I. Funding Opportunity Description
Authority: This program is authorized
in sections 104(i) (1)(E), (7), (9), and (15)
of the Comprehensive Environmental
Response, Compensation, and Liability
Act (CERCLA) as amended by the
Superfund Amendments and
Reauthorization Act (SARA) [42 U.S.C.
9604(i)(1)(E), (7), (9), and (15)].
Background: Agency for Toxic
Substances and Disease Registry
(ATSDR) has the responsibility under
Comprehensive Environmental
Response, Compensation, and Liability
Act (CERCLA), as amended, to evaluate
the relationship between exposures to
hazardous substances and adverse
human health effects. However, this
relationship between exposures to
hazardous substances and adverse
health effects is complicated and
difficult to evaluate. Many factors can
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
E:\FR\FM\04AUN1.SGM
04AUN1
44926
Federal Register / Vol. 70, No. 149 / Thursday, August 4, 2005 / Notices
the priority health conditions of lung
and respiratory disease.
Exposure to Contaminants from
Collapse of World Trade Center Towers
on September 11, 2001
The World Trade Center Health
Registry is a joint effort of ATSDR and
the New York City Department of Health
and Mental Hygiene (NYCDOHMH). It
was designed to track the health of
people who were most directly exposed
to the disaster on September 11, 2001,
and in the months that followed.
Registrants will be followed to attempt
to determine if their exposure to smoke,
dust, and airborne substances from the
collapse of the towers and subsequent
fires has a long term impact on their
health. Questions regarding their
physical and mental health were asked
in a structured interview of
approximately 30 minutes. Data
collection was completed over
approximately 15 months and over
71,000 people enrolled in the registry.
Environmental monitoring information
indicates that possible exposure to
asbestos, particulate matter, manmade
vitrious fibers, silica, Polycyclic
Aromatic Hydrocarbons (PAHs), and
other caustic material may have
occurred. Several of these materials are
associated with short- and long-term
health effects. Some preliminary followup studies of people in lower Manhattan
have found some associations between
those exposures and respiratory health
problems. Additional research is needed
to better clarify the exposure and dose
relationship. In addition, research is
needed to determine the possible future
occurrence of adverse health effects.
This work addresses the priority health
conditions of lung and respiratory
disease.
Purpose: The purpose of this program
is to fill gaps in knowledge by
conducting applied research studies
related to human exposure to hazardous
substances at hazardous waste sites and
adverse health outcomes, including
health outcomes as prioritized by
ATSDR. This program addresses the
‘‘Healthy People 2010’’ focus areas of
Environmental Health and Public
Health Infrastructure.
Measurable outcomes of the program
will be in alignment with the following
performance goal for the ATSDR:
• Determine human health effects
associated with exposures from
hazardous waste sites to Superfundrelated priority hazardous substances.
Hazardous substances, as applies to
this announcement, are those as defined
by the Comprehensive Environmental,
Response, Compensation, and Liability
Act (CERCLA). The list of priority
VerDate jul<14>2003
16:23 Aug 03, 2005
Jkt 205001
hazardous substances found at CERCLA
sites can be found at https://
www.atsdr.cdc.gov/clist.html.
Research Objectives: Studies may be
conducted in the following areas:
• Identification, validation, and
development of biomarkers of exposure,
susceptibility, and effect;
• Further evaluation of the link or
lack of linkage between specific
chemicals and specific health effects
and
• Development of research projects to
further investigate outcomes found in
data previously collected by ATSDR or
its grantees.
Activities: Awardee activities for this
program are as follows:
Applications must propose studies
which will address one or more of the
following ATSDR Priority Health
Conditions: (in alphabetic order)
• Birth defects and reproductive
disorders;
• Cancers (selected anatomic sites);
• Immune function disorders;
• Kidney dysfunction;
• Liver dysfunction
• Lung and respiratory diseases; and
• Neurotoxic disorders.
Applicants must propose studies/
projects in one or more of any of the
following areas of investigation:
• Identify risk factors for adverse
health effects in populations that have
either potential or known exposures to
hazardous substances (as defined by
CERCLA) from hazardous waste sites
and releases.
• Evaluate potentially impacted
populations exposed to the events of the
collapse of the World Trade Center
Towers on 9/11 and/or exposed to ore
from the Libby, MT mine to identify
linkages between exposure and adverse
health effects and those risk factors
which may be impacted by prevention
actions. See summaries of these ATSDR
activities under the Background section
of this RFA.
• Develop methods to identify
adverse health effects in populations
that are potentially exposed to
hazardous substances from hazardous
waste sites in their environment. This
includes medical research to evaluate
currently available biological tests
(biomarkers) and disease occurrence in
potentially impacted populations such
as individuals exposed to vermiculite
contaminated with asbestos from the
Libby, MT mine. See summary of this
ATSDR activity under the Background
section of this RFA.
• Disseminate research findings upon
satisfactory completion of peer and
public review. Findings should be
disseminated through presentations at
scientific meetings, participation in
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
stakeholder or state sponsored meetings,
and/or journal publications.
II. Award Information
Type of Award: Grant.
Mechanism of Support: R01.
Fiscal Year Funds: 2005.
Approximate Total Funding:
$350,000. (This amount is an estimate,
and is subject to availability of funds.)
Approximate Number of Awards:
One.
Approximate Average Award:
$350,000. (This amount is for the first
12-month budget period.)
Floor of Award Range: None.
Ceiling of Award Range: $350,000
(This ceiling is for the first 12-month
budget period.)
Anticipated Award Date: August 31,
2005.
Budget Period Length: 12 months.
Project Period Length: Three (3) years.
Throughout the project period, CDC’s
commitment to continuation of awards
will be conditioned on the availability
of funds, evidence of satisfactory
progress by the recipient (as
documented in required reports), and
the determination that continued
funding is in the best interest of the
Federal Government.
III. Eligibility Information
III.1. Eligible applicants
Assistance will be provided only to
state supported United States Schools of
Public Health who are currently
accredited by the Council on Education
of Public Health that are associated with
or have access to programs in
environmental epidemiology,
environmental sciences, clinical
medicine, and medical informatics.
Applicants must affirmatively establish
that they meet their respective State’s
legislative definition of a State entity or
political subdivision to be considered
an eligible applicant. Eligibility is
limited to these applicants because they
provide (1) the technical expertise in the
wide range of disciplines needed to
further develop the theoretical and
scientific base necessary for this
research and to develop and test for new
methodology essential to support state
and local programs; and (2) a training
ground for the nation’s future
environmental public health workforce.
This range of disciplines and expertise
is often unavailable or difficult to access
by state or local public health agencies.
III.2. Cost Sharing or Matching
Matching funds are not required for
this program.
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 70, No. 149 / Thursday, August 4, 2005 / Notices
III.3. Other
If you request a funding amount
greater than the ceiling of the award
range, your application will be
considered non-responsive, and will not
be entered into the review process. You
will be notified that your application
did not meet the submission
requirements.
Special Requirements: If your
application is incomplete or nonresponsive to the requirements listed in
this section, it will not be entered into
the review process. You will be notified
that your application did not meet
submission requirements.
• Late applications will be considered
non-responsive. See section ‘‘IV.3.
Submission Dates and Times’’ for more
information on deadlines.
• Note: Title 2 of the United States
Code Section 1611 states that an
organization described in Section
501(c)(4) of the Internal Revenue Code
that engages in lobbying activities is not
eligible to receive Federal funds
constituting an award, grant, or loan.
Individuals Eligible to Become
Principal Investigators: Any individual
with the skills, knowledge, and
resources necessary to carry out the
proposed research is invited to work
with their institution to develop an
application for support. Individuals
from underrepresented racial and ethnic
groups as well as individuals with
disabilities are always encouraged to
apply for CDC programs.
IV. Application and Submission
Information
IV.1. Address To Request Application
Package
To apply for this funding opportunity,
use application form PHS 398 (OMB
number 0925–0001 rev. 9/2004). Forms
and instructions are available in an
interactive format on the CDC Web site,
at the following Internet address: http:/
/www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also
available in an interactive format on the
National Institutes of Health (NIH) Web
site at the following Internet address:
https://grants.nih.gov/grants/funding/
phs398/phs398.html.
If you do not have access to the
Internet, or if you have difficulty
accessing the forms on-line, you may
contact the CDC Procurement and
Grants Office Technical Information
Management Section (PGO–TIM) staff
at: 770–488–2700. Application forms
can be mailed to you.
VerDate jul<14>2003
16:23 Aug 03, 2005
Jkt 205001
IV.2. Content and Form of Application
Submission
Application: Follow the PHS 398
application instructions for content and
formatting of your application. For
further assistance with the PHS 398
application form, contact PGO–TIM staff
at 770–488–2700, or contact GrantsInfo,
telephone (301) 435–0714, e-mail:
GrantsInfo@nih.gov.
You are required to have a Dun and
Bradstreet Data Universal Numbering
System (DUNS) number to apply for a
grant or cooperative agreement from the
Federal government. Your DUNS
number must be entered on line 11 of
the face page of the PHS 398 application
form. The DUNS number is a nine-digit
identification number, which uniquely
identifies business entities. Obtaining a
DUNS number is easy and there is no
charge. To obtain a DUNS number,
access https://
www.dunandbradstreet.com or call 1–
866–705–5711. For more information,
see the CDC Web site at: https://
www.cdc.gov/od/pgo/funding/
pubcommt.htm.
This announcement uses the modular
budgeting as well as non-modular
budgeting formats. See: https://
grants.nih.gov/grants/funding/modular/
modular.htm for additional guidance on
modular budgets. Specifically, if you are
submitting an application with direct
costs in each year of $250,000 or less,
use the modular budget format.
Otherwise, follow the instructions for
non-modular budget research grant
applications.
Additional requirements that may
require you to submit additional
documentation with your application
are listed in section ‘‘VI.2.
Administrative and National Policy
Requirements.’’
IV.3. Submission Dates and Times
Application Deadline Date: August
29, 2005.
Explanation of Deadlines:
Applications must be received in the
CDC Procurement and Grants Office by
4 p.m. eastern time on the deadline
date. If you submit your application by
the United States Postal Service or
commercial delivery service, you must
ensure that the carrier will be able to
guarantee delivery by the closing date
and time. If CDC receives your
submission after closing due to: (1)
carrier error, when the carrier accepted
the package with a guarantee for
delivery by the closing date and time, or
(2) significant weather delays or natural
disasters, you will be given the
opportunity to submit documentation of
the carriers guarantee. If the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
44927
documentation verifies a carrier
problem, CDC will consider the
submission as having been received by
the deadline.
This announcement is the definitive
guide on LOI and application content,
submission address, and deadline. It
supersedes information provided in the
application instructions. If your
application does not meet the deadline
above, it will not be eligible for review,
and will be discarded. You will be
notified that you did not meet the
submission requirements.
CDC will not notify you upon receipt
of your submission. If you have a
question about the receipt of your LOI
or application, first contact your courier.
If you still have a question about your
application, contact the PGO–TIM staff
at: 770–488–2700. If you still have a
question about your LOI, contact OPHR
staff at: 404–371–5253. Before calling,
please wait two to three days after the
submission deadline. This will allow
time for submissions to be processed
and logged.
IV.4. Intergovernmental Review of
Applications
Your application is subject to
Intergovernmental Review of Federal
Programs, as governed by Executive
Order (EO) 12372. This order sets up a
system for state and local governmental
review of proposed federal assistance
applications. You should contact your
state single point of contact (SPOC) as
early as possible to alert the SPOC to
prospective applications, and to receive
instructions on your state’s process.
Click on the following link to get the
current SPOC list: https://
www.whitehouse.gov/omb/grants/
spoc.html.
IV.5. Funding Restrictions
Restrictions, which must be taken into
account while writing your budget, are
as follows:
• Funds relating to the conduct of
research will not be released until the
appropriate assurances and Institutional
Review Board approvals are in place.
• Reimbursement of pre-award costs
is not allowed.
• Funds may not be used for projects
in the area of asthma-related research.
If you are requesting indirect costs in
your budget, you must include a copy
of your indirect cost rate agreement. If
your indirect cost rate is a provisional
rate, the agreement should be less than
12 months of age.
IV.6. Other Submission Requirements
Application Submission Address:
Submit the original and one copy of
your application by mail or express
E:\FR\FM\04AUN1.SGM
04AUN1
44928
Federal Register / Vol. 70, No. 149 / Thursday, August 4, 2005 / Notices
delivery service to: Technical
Information Management—CDC–RFA–
TS05–110, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta,
GA 30341.
At the time of submission, four
additional copies of the applications,
and all appendices must be sent to:
Mildred Williams-Johnson, Ph.D.,
Scientific Program Administrator, CDC/
ATSDR, 1600 Clifton Road, NE,
MailStop E17, Atlanta, GA 30333.
Telephone: 404 498–0639.
Applications may not be submitted
electronically at this time.
V. Application Review Information
V.1. Criteria
Applicants are required to provide
measures of effectiveness that will
demonstrate the accomplishment of the
various identified objectives of the
grant. Measures of effectiveness must
relate to the performance goals stated in
the ‘‘Purpose’’ section of this
announcement. Measures must be
objective and quantitative, and must
measure the intended outcome. These
measures of effectiveness must be
submitted with the application and will
be an element of evaluation.
The goals of CDC/ATSDR supported
research are to advance the
understanding of biological systems,
improve the control and prevention of
disease and injury, and enhance health.
In the written comments, reviewers will
be asked to evaluate the application in
order to judge the likelihood that the
proposed research will have a
substantial impact on the pursuit of
these goals.
The scientific review group will
address and consider each of the
following criteria equally in assigning
the application’s overall score,
weighting them as appropriate for each
application. The application does not
need to be strong in all categories to be
judged likely to have major scientific
impact and thus deserve a high priority
score. For example, an investigator may
propose to carry out important work
that by its nature is not innovative, but
is essential to move a field forward.
The review criteria are as follows:
Significance: Does this study address
an important problem? If the aims of the
application are achieved, how will
scientific knowledge be advanced? The
study should include the rationale for
selecting a community and population
to be the subject of the proposed
investigation and the relevance to
exposures to hazardous substances at
hazardous waste sites and adverse
health outcomes.
Approach: Does the applicant provide
a sound rationale for the specific
VerDate jul<14>2003
16:23 Aug 03, 2005
Jkt 205001
approach and scientific method to
conduct the study? Are the conceptual
framework, design, methods, and
analyses adequately developed, wellintegrated, and appropriate to the aims
of the project? Does the applicant
acknowledge potential problem areas
and consider alternative tactics? Is there
(a) an adequate rationale for the design
of the proposed study; (b) identification
of a target (exposed/diseased)
population; (c) identification of an
appropriate comparison group (if
warranted); (d) consideration of sample
size; (e) a plan for linking
environmental exposure to hazardous
substances and health outcome data;
and (f) detailed plan for analysis of the
data included.
Investigator: Is the investigator
appropriately trained and well suited to
carry out this work? Is the work
proposed appropriate to the experience
level of the principal investigator and
other researchers (if any)?
Environment: Does the scientific
environment in which the work will be
done contribute to the probability of
success? Do the proposed studies take
advantage of unique features of the
scientific environment or employ useful
collaborative arrangements? Is there
evidence of adequate institutional
support? Are there letters of support, if
appropriate?
Additional Review Criteria: In
addition to the above criteria, the
following items will be considered in
the determination of scientific merit and
priority score:
Protection of Human Subjects from
Research Risks: Does the application
adequately address the requirements of
title 45 CFR part 46 for the protection
of human subjects? The involvement of
human subjects and protections from
research risk relating to their
participation in the proposed research
will be assessed.
Inclusion of Women and Minorities in
Research: Does the application
adequately address the CDC Policy
requirements regarding the inclusion of
women, ethnic, and racial groups in the
proposed research? This includes: (1)
The proposed plan for the inclusion of
both sexes and racial and ethnic
minority populations for appropriate
representation; (2) the proposed
justification when representation is
limited or absent; (3) a statement as to
whether the design of the study is
adequate to measure differences when
warranted; and (4) a statement as to
whether the plans for recruitment and
outreach for study participants include
the process of establishing partnerships
with community(ies) and recognition of
mutual benefits.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Budget: The reasonableness of the
proposed budget and the requested
period of support in relation to the
proposed research.
V.2. Review and Selection Process
Applications will be reviewed for
completeness by the Procurement and
Grants Office (PGO) and for
responsiveness by the Office of Public
Health Research. Incomplete
applications and applications that are
non-responsive to the eligibility criteria
will not advance through the review
process. Applicants will be notified that
their application did not meet
submission requirements.
Applications that are complete and
responsive to the announcement will be
evaluated for scientific and technical
merit by an appropriate review group or
charter study section convened by
ATSDR in accordance with the review
criteria listed above. As part of the
initial merit review, all applications
may:
• Undergo a process in which only
those applications deemed to have the
highest scientific merit by the review
group, generally the top half of the
applications under review, will be
discussed and assigned a priority score.
• Receive a written critique.
• Receive a second programmatic
level review conducted by the Scientific
Program Administrator in the Office of
the Associate Director for Science.
Award Criteria: Criteria that will be
used to make award decisions during
the programmatic review include:
• Scientific merit.
• Availability of funds.
• Programmatic priorities.
V.3. Anticipated Announcement and
Award Dates
The anticipated award date will be on
or before August 31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a
Notice of Award (NoA) from the CDC
Procurement and Grants Office. The
NoA shall be the only binding,
authorizing document between the
recipient and CDC. The NoA will be
signed by an authorized Grants
Management Officer, and mailed to the
recipient fiscal officer identified in the
application.
Unsuccessful applicants will receive
notification of the results of the
application review by mail.
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 70, No. 149 / Thursday, August 4, 2005 / Notices
VI.2. Administrative and National
Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of
Federal Regulations, see the National
Archives and Records Administration at
the following Internet address: https://
www.access.gpo.gov/nara/cfr/cfr-tablesearch.html.
The following additional
requirements apply to this project:
• AR–1 Human Subjects
Requirements.
• AR–2 Requirements for Inclusion
of Women and Racial and Ethnic
Minorities in Research.
• AR–7 Executive Order 12372.
• AR–9 Paperwork Reduction Act
Requirements.
• AR–10 Smoke-Free Workplace
Requirements.
• AR–11 Healthy People 2010.
• AR–12 Lobbying Restrictions.
• AR–14 Accounting System
Requirements.
• AR–17 Peer and Technical
Reviews of Final Reports of Health
Studies-ATSDR.
• AR–18 Cost Recovery-ATSDR.
• AR–19 Third Party AgreementsATSDR.
• AR–22 Research Integrity.
Additional information on these
requirements can be found on the CDC
Web site at the following Internet
address: https://www.cdc.gov/od/pgo/
funding/ARs.htm.
VI.3. Reporting
You must provide ATSDR with an
original, plus two hard copies of the
following reports:
1. Interim progress report, (use form
PHS 2590, OMB Number 0925–0001,
rev. 9/2004 as posted on the CDC
website) no less than 90 days before the
end of the budget period. The progress
report will serve as your non-competing
continuation application, and must
contain the following additional
elements:
a. Progress toward Measures of
Effectiveness.
b. Additional Information Requested
by Program.
2. Financial status report, no more
than 90 days after the end of the budget
period.
3. Final financial and performance
reports, no more than 90 days after the
end of the project period. Final
performance reports should include a
scientific report that summarizes the
complete project, the analyses and the
final results, and/or a manuscript
suitable for publication in a peer review
journal. Additionally, the Program office
requests that all data sets generated
VerDate jul<14>2003
16:23 Aug 03, 2005
Jkt 205001
under this project be provided to
ATSDR in electronic format.
These reports must be mailed to the
Grants Management Specialist listed in
the ‘‘Agency Contacts’’ section of this
announcement.
VII. Agency Contacts
We encourage inquiries concerning
this announcement.
For general questions, contact:
Technical Information Management
Section, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta,
GA 30341. Telephone: 770 488–2700.
For scientific/research issues, contact:
Mildred Williams-Johnson, Ph.D.,
Scientific Program Administrator, CDC/
ATSDR, 1600 Clifton Road, NE,
MailStop E17, Atlanta, GA 30333.
Telephone: 404 498–0639. E-mail:
MWilliams-Johnson@cdc.gov.
Or,
Sharon Campolucci, RN, MSN,
Scientific Collaborator, CDC/ATSDR,
1600 Clifton Road, NE, MailStop E31,
Atlanta, GA 30333. Telephone: 404–
498–0105. E-mail: ssc1@cdc.gov.
For financial, grants management, or
budget assistance, contact: Edna Green,
Grants Management Specialist, CDC
Procurement and Grants Office, 2920
Brandywine Road, Atlanta, GA 30341.
Telephone: 770 488–2743. E-mail:
egreen@cdc.gov.
VIII. Other Information
This and other CDC funding
opportunity announcements can be
found on the CDC Web site, Internet
address: https://www.cdc.gov. Click on
‘‘Funding’’ then ‘‘Grants and
Cooperative Agreements.’’
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–15412 Filed 8–3–05; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Request for Application (RFA) AA103]
Rapid Strengthening and Expansion of
Integrated Social Services for People
Living With HIV/AIDS (PLWHA) in
Mozambique; Notice of Intent To Fund
Single Eligibility Award
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to award fiscal year (FY) 2005 funds for
a cooperative agreement program to
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
44929
provide anti-retroviral therapy (ART) to
110,000 people, care and support to
550,000 people, and preventing 506,379
new infections over the five years of
emergency plan implementation in
Mozambique. Key strategies include
strengthening the capacity of national
institutions, such as the Ministry of
Health (MOH), the National AIDS
Council (NAC) and the Ministry of
Women and Social Welfare (MMAS), in
order for them to develop and update
national HIV/AIDS plans, strategies,
guidelines, and training materials
needed to institute services.
The Catalog of Federal Domestic
Assistance number for this program is
93.067.
B. Eligible Applicant
Applications may be submitted by the
Ministry of Women and Social Welfare
´
(Ministerio da Mulher e Accao Social)
¸˜
(MMAS) of the Republic of
Mozambique. No other applications are
solicited.
The Government of Mozambique has
assigned overall responsibility to
MMAS for coordinating care for orphans
and vulnerable children and home visits
for psychosocial support to PLWHA.
The MOH is tasked with coordinating
home health-care programs. To fulfill its
mission to assist persons infected with
or affected by HIV/AIDS, MMAS will
need to work with a variety of
organizations that provide social
services, and with the MOH, to ensure
smooth integration, avoiding the
duplication of services. The purpose of
this cooperative agreement is to enhance
the ability of MMAS to coordinate these
important HIV/AIDS mitigating
activities.
C. Funding
Approximately $800,000 is available
in FY 2005 to fund this award. It is
expected that the award will begin on or
before August 31, 2005, and will be
made for a 12-month budget period
within a project period of up to four
years. Funding estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146, Telephone: 770–488–2700.
For program technical assistance,
contact: David Nelson, Project Officer,
CDC/American Embassy, 2330 Maputo
Place, Washington, DC 20521–2330,
Telephone: 258 131 4747, E-mail:
Nelsond@cdcmz.org.
E:\FR\FM\04AUN1.SGM
04AUN1
Agencies
[Federal Register Volume 70, Number 149 (Thursday, August 4, 2005)]
[Notices]
[Pages 44925-44929]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15412]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
Applied Research for Populations Around Hazardous Waste Sites
Announcement Type: New.
Funding Opportunity Number: CDC-RFA-TS05-110.
Catalog of Federal Domestic Assistance Number: 93.161.
DATES: Application Deadline: August 29, 2005.
I. Funding Opportunity Description
Authority: This program is authorized in sections 104(i) (1)(E),
(7), (9), and (15) of the Comprehensive Environmental Response,
Compensation, and Liability Act (CERCLA) as amended by the Superfund
Amendments and Reauthorization Act (SARA) [42 U.S.C. 9604(i)(1)(E),
(7), (9), and (15)].
Background: Agency for Toxic Substances and Disease Registry
(ATSDR) has the responsibility under Comprehensive Environmental
Response, Compensation, and Liability Act (CERCLA), as amended, to
evaluate the relationship between exposures to hazardous substances and
adverse human health effects. However, this relationship between
exposures to hazardous substances and adverse health effects is
complicated and difficult to evaluate. Many factors can generate the
appearance or hide the presence of a relationship between exposure to
hazardous substances and adverse health effects. The presence of
environmental contamination and an adverse health effect does not
automatically demonstrate evidence of a causal relationship. Beginning
in 1992, ATSDR developed a research agenda to address some of these
questions. Research under this agenda continues to be conducted, but
additional research is needed. Therefore, projects conducted under this
program announcement will focus on those questions that have the
greatest relevance toward determining the relationship of adverse
health effects among persons exposed to hazardous substances.
Examples of relevant ATSDR activities are presented below:
Evaluation of Persons Exposed to Tremolite Asbestos Contaminated
Vermiculite
Asbestos contaminated vermiculite ore was mined and processed in
Libby, Montana, from the early 1920s until 1990. ATSDR has completed a
medical screening program, a mortality review and a Public Health
assessment in Libby. Based on these studies and additional evaluation
conducted by ATSDR, EPA and the State of Montana, people who worked in
the Libby mine or processing facilities and people who lived in the
Libby community were exposed to asbestos-contaminated vermiculite.
Nearly eighteen percent of medical screening participants had
radiographic pleural abnormalities consistent with asbestos exposure.
Mortality due to lung cancer and asbestosis was also found to be
elevated in Libby. ATSDR has also implemented a Tremolite Asbestos
Registry (TAR) of exposed persons and has funded the State of Montana
to conduct additional periodic medical surveillance for eligible
persons.
Additionally, records indicate that the vermiculite ore from Libby
was shipped to over 200 locations around the U.S. for handling and/or
processing into various commercial and consumer products. Twenty-eight
``Phase 1 Sites'' have been identified based on a variety of factors
such as tonnage of ore received, population density, numbers of
workers, etc. Health statistics reviews (to evaluate mortality and
cancer registry data) are currently being completed in sixteen states
and mesothelioma surveillance has been initiated in three states (New
York, Wisconsin and New Jersey). In addition, ATSDR has funded a
comprehensive community exposure assessment project in a community
receiving the ore. This work addresses
[[Page 44926]]
the priority health conditions of lung and respiratory disease.
Exposure to Contaminants from Collapse of World Trade Center Towers on
September 11, 2001
The World Trade Center Health Registry is a joint effort of ATSDR
and the New York City Department of Health and Mental Hygiene
(NYCDOHMH). It was designed to track the health of people who were most
directly exposed to the disaster on September 11, 2001, and in the
months that followed. Registrants will be followed to attempt to
determine if their exposure to smoke, dust, and airborne substances
from the collapse of the towers and subsequent fires has a long term
impact on their health. Questions regarding their physical and mental
health were asked in a structured interview of approximately 30
minutes. Data collection was completed over approximately 15 months and
over 71,000 people enrolled in the registry. Environmental monitoring
information indicates that possible exposure to asbestos, particulate
matter, manmade vitrious fibers, silica, Polycyclic Aromatic
Hydrocarbons (PAHs), and other caustic material may have occurred.
Several of these materials are associated with short- and long-term
health effects. Some preliminary follow-up studies of people in lower
Manhattan have found some associations between those exposures and
respiratory health problems. Additional research is needed to better
clarify the exposure and dose relationship. In addition, research is
needed to determine the possible future occurrence of adverse health
effects. This work addresses the priority health conditions of lung and
respiratory disease.
Purpose: The purpose of this program is to fill gaps in knowledge
by conducting applied research studies related to human exposure to
hazardous substances at hazardous waste sites and adverse health
outcomes, including health outcomes as prioritized by ATSDR. This
program addresses the ``Healthy People 2010'' focus areas of
Environmental Health and Public Health Infrastructure.
Measurable outcomes of the program will be in alignment with the
following performance goal for the ATSDR:
Determine human health effects associated with exposures
from hazardous waste sites to Superfund-related priority hazardous
substances.
Hazardous substances, as applies to this announcement, are those as
defined by the Comprehensive Environmental, Response, Compensation, and
Liability Act (CERCLA). The list of priority hazardous substances found
at CERCLA sites can be found at https://www.atsdr.cdc.gov/clist.html.
Research Objectives: Studies may be conducted in the following
areas:
Identification, validation, and development of biomarkers
of exposure, susceptibility, and effect;
Further evaluation of the link or lack of linkage between
specific chemicals and specific health effects and
Development of research projects to further investigate
outcomes found in data previously collected by ATSDR or its grantees.
Activities: Awardee activities for this program are as follows:
Applications must propose studies which will address one or more of
the following ATSDR Priority Health Conditions: (in alphabetic order)
Birth defects and reproductive disorders;
Cancers (selected anatomic sites);
Immune function disorders;
Kidney dysfunction;
Liver dysfunction
Lung and respiratory diseases; and
Neurotoxic disorders.
Applicants must propose studies/projects in one or more of any of
the following areas of investigation:
Identify risk factors for adverse health effects in
populations that have either potential or known exposures to hazardous
substances (as defined by CERCLA) from hazardous waste sites and
releases.
Evaluate potentially impacted populations exposed to the
events of the collapse of the World Trade Center Towers on 9/11 and/or
exposed to ore from the Libby, MT mine to identify linkages between
exposure and adverse health effects and those risk factors which may be
impacted by prevention actions. See summaries of these ATSDR activities
under the Background section of this RFA.
Develop methods to identify adverse health effects in
populations that are potentially exposed to hazardous substances from
hazardous waste sites in their environment. This includes medical
research to evaluate currently available biological tests (biomarkers)
and disease occurrence in potentially impacted populations such as
individuals exposed to vermiculite contaminated with asbestos from the
Libby, MT mine. See summary of this ATSDR activity under the Background
section of this RFA.
Disseminate research findings upon satisfactory completion
of peer and public review. Findings should be disseminated through
presentations at scientific meetings, participation in stakeholder or
state sponsored meetings, and/or journal publications.
II. Award Information
Type of Award: Grant.
Mechanism of Support: R01.
Fiscal Year Funds: 2005.
Approximate Total Funding: $350,000. (This amount is an estimate,
and is subject to availability of funds.)
Approximate Number of Awards: One.
Approximate Average Award: $350,000. (This amount is for the first
12-month budget period.)
Floor of Award Range: None.
Ceiling of Award Range: $350,000 (This ceiling is for the first 12-
month budget period.)
Anticipated Award Date: August 31, 2005.
Budget Period Length: 12 months.
Project Period Length: Three (3) years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
III. Eligibility Information
III.1. Eligible applicants
Assistance will be provided only to state supported United States
Schools of Public Health who are currently accredited by the Council on
Education of Public Health that are associated with or have access to
programs in environmental epidemiology, environmental sciences,
clinical medicine, and medical informatics. Applicants must
affirmatively establish that they meet their respective State's
legislative definition of a State entity or political subdivision to be
considered an eligible applicant. Eligibility is limited to these
applicants because they provide (1) the technical expertise in the wide
range of disciplines needed to further develop the theoretical and
scientific base necessary for this research and to develop and test for
new methodology essential to support state and local programs; and (2)
a training ground for the nation's future environmental public health
workforce. This range of disciplines and expertise is often unavailable
or difficult to access by state or local public health agencies.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
[[Page 44927]]
III.3. Other
If you request a funding amount greater than the ceiling of the
award range, your application will be considered non-responsive, and
will not be entered into the review process. You will be notified that
your application did not meet the submission requirements.
Special Requirements: If your application is incomplete or non-
responsive to the requirements listed in this section, it will not be
entered into the review process. You will be notified that your
application did not meet submission requirements.
Late applications will be considered non-responsive. See
section ``IV.3. Submission Dates and Times'' for more information on
deadlines.
Note: Title 2 of the United States Code Section 1611
states that an organization described in Section 501(c)(4) of the
Internal Revenue Code that engages in lobbying activities is not
eligible to receive Federal funds constituting an award, grant, or
loan.
Individuals Eligible to Become Principal Investigators: Any
individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are
always encouraged to apply for CDC programs.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 9/2004). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: https://www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) Web site at the following
Internet address: https://grants.nih.gov/grants/funding/phs398/
phs398.html.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Application Submission
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at 770-488-2700, or
contact GrantsInfo, telephone (301) 435-0714, e-mail:
GrantsInfo@nih.gov.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access https://www.dunandbradstreet.com
or call 1-866-705-5711. For more information, see the CDC Web site at:
https://www.cdc.gov/od/pgo/funding/pubcommt.htm.
This announcement uses the modular budgeting as well as non-modular
budgeting formats. See: https://grants.nih.gov/grants/funding/modular/
modular.htm for additional guidance on modular budgets. Specifically,
if you are submitting an application with direct costs in each year of
$250,000 or less, use the modular budget format. Otherwise, follow the
instructions for non-modular budget research grant applications.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
Application Deadline Date: August 29, 2005.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. eastern time on the deadline
date. If you submit your application by the United States Postal
Service or commercial delivery service, you must ensure that the
carrier will be able to guarantee delivery by the closing date and
time. If CDC receives your submission after closing due to: (1) carrier
error, when the carrier accepted the package with a guarantee for
delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the submission as having
been received by the deadline.
This announcement is the definitive guide on LOI and application
content, submission address, and deadline. It supersedes information
provided in the application instructions. If your application does not
meet the deadline above, it will not be eligible for review, and will
be discarded. You will be notified that you did not meet the submission
requirements.
CDC will not notify you upon receipt of your submission. If you
have a question about the receipt of your LOI or application, first
contact your courier. If you still have a question about your
application, contact the PGO-TIM staff at: 770-488-2700. If you still
have a question about your LOI, contact OPHR staff at: 404-371-5253.
Before calling, please wait two to three days after the submission
deadline. This will allow time for submissions to be processed and
logged.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for state and local governmental review of proposed federal
assistance applications. You should contact your state single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your state's process.
Click on the following link to get the current SPOC list: https://
www.whitehouse.gov/omb/grants/spoc.html.
IV.5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows:
Funds relating to the conduct of research will not be
released until the appropriate assurances and Institutional Review
Board approvals are in place.
Reimbursement of pre-award costs is not allowed.
Funds may not be used for projects in the area of asthma-
related research.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
IV.6. Other Submission Requirements
Application Submission Address: Submit the original and one copy of
your application by mail or express
[[Page 44928]]
delivery service to: Technical Information Management--CDC-RFA-TS05-
110, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta,
GA 30341.
At the time of submission, four additional copies of the
applications, and all appendices must be sent to: Mildred Williams-
Johnson, Ph.D., Scientific Program Administrator, CDC/ATSDR, 1600
Clifton Road, NE, MailStop E17, Atlanta, GA 30333. Telephone: 404 498-
0639.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
Applicants are required to provide measures of effectiveness that
will demonstrate the accomplishment of the various identified
objectives of the grant. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
The goals of CDC/ATSDR supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease and injury, and enhance health. In the written comments,
reviewers will be asked to evaluate the application in order to judge
the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals.
The scientific review group will address and consider each of the
following criteria equally in assigning the application's overall
score, weighting them as appropriate for each application. The
application does not need to be strong in all categories to be judged
likely to have major scientific impact and thus deserve a high priority
score. For example, an investigator may propose to carry out important
work that by its nature is not innovative, but is essential to move a
field forward.
The review criteria are as follows:
Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? The study should include the rationale for selecting a
community and population to be the subject of the proposed
investigation and the relevance to exposures to hazardous substances at
hazardous waste sites and adverse health outcomes.
Approach: Does the applicant provide a sound rationale for the
specific approach and scientific method to conduct the study? Are the
conceptual framework, design, methods, and analyses adequately
developed, well-integrated, and appropriate to the aims of the project?
Does the applicant acknowledge potential problem areas and consider
alternative tactics? Is there (a) an adequate rationale for the design
of the proposed study; (b) identification of a target (exposed/
diseased) population; (c) identification of an appropriate comparison
group (if warranted); (d) consideration of sample size; (e) a plan for
linking environmental exposure to hazardous substances and health
outcome data; and (f) detailed plan for analysis of the data included.
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
studies take advantage of unique features of the scientific environment
or employ useful collaborative arrangements? Is there evidence of
adequate institutional support? Are there letters of support, if
appropriate?
Additional Review Criteria: In addition to the above criteria, the
following items will be considered in the determination of scientific
merit and priority score:
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of title 45 CFR part 46
for the protection of human subjects? The involvement of human subjects
and protections from research risk relating to their participation in
the proposed research will be assessed.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of women, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) the proposed justification when representation is limited or
absent; (3) a statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) a statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
community(ies) and recognition of mutual benefits.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) and for responsiveness by the Office of Public
Health Research. Incomplete applications and applications that are non-
responsive to the eligibility criteria will not advance through the
review process. Applicants will be notified that their application did
not meet submission requirements.
Applications that are complete and responsive to the announcement
will be evaluated for scientific and technical merit by an appropriate
review group or charter study section convened by ATSDR in accordance
with the review criteria listed above. As part of the initial merit
review, all applications may:
Undergo a process in which only those applications deemed
to have the highest scientific merit by the review group, generally the
top half of the applications under review, will be discussed and
assigned a priority score.
Receive a written critique.
Receive a second programmatic level review conducted by
the Scientific Program Administrator in the Office of the Associate
Director for Science.
Award Criteria: Criteria that will be used to make award decisions
during the programmatic review include:
Scientific merit.
Availability of funds.
Programmatic priorities.
V.3. Anticipated Announcement and Award Dates
The anticipated award date will be on or before August 31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Award (NoA) from the
CDC Procurement and Grants Office. The NoA shall be the only binding,
authorizing document between the recipient and CDC. The NoA will be
signed by an authorized Grants Management Officer, and mailed to the
recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
[[Page 44929]]
VI.2. Administrative and National Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: https://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-1 Human Subjects Requirements.
AR-2 Requirements for Inclusion of Women and Racial and
Ethnic Minorities in Research.
AR-7 Executive Order 12372.
AR-9 Paperwork Reduction Act Requirements.
AR-10 Smoke-Free Workplace Requirements.
AR-11 Healthy People 2010.
AR-12 Lobbying Restrictions.
AR-14 Accounting System Requirements.
AR-17 Peer and Technical Reviews of Final Reports of
Health Studies-ATSDR.
AR-18 Cost Recovery-ATSDR.
AR-19 Third Party Agreements-ATSDR.
AR-22 Research Integrity.
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: https://www.cdc.gov/od/
pgo/funding/ARs.htm.
VI.3. Reporting
You must provide ATSDR with an original, plus two hard copies of
the following reports:
1. Interim progress report, (use form PHS 2590, OMB Number 0925-
0001, rev. 9/2004 as posted on the CDC website) no less than 90 days
before the end of the budget period. The progress report will serve as
your non-competing continuation application, and must contain the
following additional elements:
a. Progress toward Measures of Effectiveness.
b. Additional Information Requested by Program.
2. Financial status report, no more than 90 days after the end of
the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period. Final performance reports should
include a scientific report that summarizes the complete project, the
analyses and the final results, and/or a manuscript suitable for
publication in a peer review journal. Additionally, the Program office
requests that all data sets generated under this project be provided to
ATSDR in electronic format.
These reports must be mailed to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
We encourage inquiries concerning this announcement.
For general questions, contact: Technical Information Management
Section, CDC Procurement and Grants Office, 2920 Brandywine Road,
Atlanta, GA 30341. Telephone: 770 488-2700.
For scientific/research issues, contact: Mildred Williams-Johnson,
Ph.D., Scientific Program Administrator, CDC/ATSDR, 1600 Clifton Road,
NE, MailStop E17, Atlanta, GA 30333. Telephone: 404 498-0639. E-mail:
MWilliams-Johnson@cdc.gov.
Or,
Sharon Campolucci, RN, MSN, Scientific Collaborator, CDC/ATSDR,
1600 Clifton Road, NE, MailStop E31, Atlanta, GA 30333. Telephone: 404-
498-0105. E-mail: ssc1@cdc.gov.
For financial, grants management, or budget assistance, contact:
Edna Green, Grants Management Specialist, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: 770 488-
2743. E-mail: egreen@cdc.gov.
VIII. Other Information
This and other CDC funding opportunity announcements can be found
on the CDC Web site, Internet address: https://www.cdc.gov. Click on
``Funding'' then ``Grants and Cooperative Agreements.''
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
[FR Doc. 05-15412 Filed 8-3-05; 8:45 am]
BILLING CODE 4163-70-P